Evidence map›Paper›PMID 39594819›Full record

ReviewCancers2024

Response to Bridging Therapy as a Prognostic Indicator of Post-Transplantation Hepatocellular Carcinoma Recurrence and Survival: A Systematic Review.

Paweł Topolewski, Dariusz Łaski, Martyna Łukasiewicz, Piotr Domagała, Roeland F de Wilde, Wojciech G Polak

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paweł TopolewskiDivision of Quality in Healthcare, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-7824-5767
Dariusz ŁaskiDepartment of Surgical Oncology, Transplant Surgery and General Surgery, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-1177-4541
Martyna ŁukasiewiczDivision of Quality in Healthcare, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-8816-1030
Piotr DomagałaDepartment of Surgical Oncology, Transplant Surgery and General Surgery, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
Roeland F de WildeErasmus MC Transplant Institute, University Medical Center Rotterdam, Department of HPB- & Transplant Surgery, 3015 GD Rotterdam, The Netherlands.
Wojciech G PolakDepartment of Surgical Oncology, Transplant Surgery and General Surgery, Medical University of Gdańsk, 80-210 Gdańsk, Poland.ORCID 0000-0002-3096-4893

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation (LT) is one of the most effective treatments for hepatocellular carcinoma (HCC) in cirrhotic livers. Neoadjuvant bridging treatment in patients qualifying and listed for LT is advised but is still debatable owing to the low level of evidence. The aim of this study was to perform a systematic review to assess the prognostic value of bridging therapy, in terms of radiological and histopathological examination outcomes, for survival after LT. The systematic review was performed according to the PRISMA 2020 guidelines. The MEDLINE and Web of Science databases were searched. In total, five studies were included. An evaluation with the ROBINS-I resulted in studies classified as the following: moderate risk of bias (

Indexed as

bridginghepatocellular carcinomaliver transplantationlocoregional therapyMilan criteriathermal ablationtransarterial chemoembolizationtransplant oncology

Identifiers

PMID39594819
PMCPMC11592521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.